Trial Profile
Clinical Trials Insight: 700034422
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Jun 2008
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Seliciclib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- Sponsors Cyclacel
- 11 Jun 2008 New trial record.